Enanta Pharmaceuticals, Inc. has filed an 8-K report disclosing that on March 20, 2026, the United States Court of Appeals for the Federal Circuit scheduled oral arguments for the company's appeal against Pfizer Inc. This appeal relates to a lawsuit filed by Enanta on February 3, 2025, concerning alleged infringement of U.S. Patent No. 11,358,953, which pertains to the manufacture, use, and sale of Pfizer's COVID-19 antiviral, Paxlovid (nirmatrelvir tablets; ritonavir tablets). The outcome of this appeal could have significant implications for Enanta's financial position and market strategy, particularly in the context of its ongoing efforts to protect its intellectual property rights in the competitive pharmaceutical landscape. The scheduled oral argument is set for May 11, 2026, and the company is keenly awaiting the court's decision, which may influence its future operations and financial health.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.